


A3
cont. -



The amendments to the claims are to correct typographical errors. No new matter has been added.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Carolyn S. Elmore
Carolyn S. Elmore
Registration No. 37,567
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133


Dated: 5/2/08



MARKED UP VERSION OF AMENDMENTS

Claim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)



12. (Amended) The polymer [of] or copolymer of Claim 11, wherein the polymer or copolymer is characterized by repeat units of the formula:




wherein R_7 is a substituted or unsubstituted lower alkylene group having from 1 to about 24 carbon atoms and each X^- , separately or taken together, is a physiologically acceptable anion.

13. (Amended) The polymer [of] or copolymer of Claim 11 wherein the polymer or copolymer is characterized by repeat units of formula X or XI:

-ii-



38. (Amended) The polymer or copolymer of [C laim] Claim 36 wherein the polymer or copolymer is characterized by repeat units of formula XVI or XVII:



(XVI)

-iii-




TABLE 1
Polymer MIC(ug/ml)

Formula #													
S.aureus (ATCC 29213)													
MRSA (5 strains) ⁽¹⁾													
GISA (5 strains) ⁽²⁾													
E. faecalis (ATCC 29212)													
VRE (4 strains)													
P. aeruginosa (ATCC 27853)													
Candida*													
B. cepacia													
Oral pathogens **													
C.difficile													
H. pylori (Win)													
E. coli (ATCC 25922)													
S. marcescens													
VIII	0.65	1-2	1	1	1-3	10.4	0.65-1.3	41.5	nd	0.65	0.2	1.3	3
II	0.31	1.9	≤0.125	0.31	0.3	1.3	1.3-2.6	5.2	nd	<0.16	0.2	.65	3
IV	0.65	2.2-3.8	nd	0.65	2-2.6	2.6	0.32-2.6	5.2	nd	nd	3	1.3	9
II	1.8	1-2.6	nd	1	1-2	9	3-28	28	nd	nd	1	1	3
III	1.4	0.4-1.8	nd	3	1-3	9	1-3	28	nd	nd	2	3	3
XII	0.31	0.3-0.5	nd	0.3	0.3	0.31	0.16-2.6	41.5	nd	nd	nd	2.6	3
XIX	0.65	1	0.5	1	1-3	0.65	1.3-2.6	41.5	<10	nd	1	2.6	3
XX	1.3	2.2-3	16	1	1-3	1.3	2.6	5.2	<10	<0.16	0.4	1.3	3
XXIII	1	1.4-2.2	nd	1	1-3	9	3	9	nd	nd	1	3	3
IX+	1	nd	nd	0.3	nd	83	1-9	28	nd	nd	nd	3	28
IX++	1	1	nd	3	3-20	83	1-9	9	nd	nd	0.7	3	9
IX+++	0.65	nd	8	1.25	nd	5.2	0.65-1.3	5.2	<10	2.5	1.3	2.6	3

* 3 strains *C. glabrata*, 6 strains *C. albicans*, 2 strains *C. tropicalis*, 2 strains *C. Krusei*; ** including: *Actinobacillus actinomycetemcomitans*, *Porphyromonas gingivalis*, *Prevotella intermedia*, *Campylobacter rectus*, *Treponema denticola*, *Streptococcus intermedius*, *Fusobacterium nucleatum*, *Streptococcus gordonii*, and *Actinomyces viscosus*; ¹ methicillin resistant *Staphylococcus aureus*; ² glycopeptide intermediate *Staphylococcus aureus*; + (where R7 is butyl), ++ (where R7 is decyl), +++ (where R7 is dodecyl)

12/19

12/19